Parkinson Disease

Excellence Forums

Leaders in the field sharing authoritative insights and institutional best practices.
In this podcast, Joohi Jimenez-Shahed, MD, discusses the findings of the study, “Safety, Tolerability, and Pharmacodynamic Profile of DNL201 at dose levels demonstrating LRRK2 inhibition in Parkinson's Disease Patients with and without LRRK2 mutations,” which was presented at the International Parkinson and Movement Disorder Society Virtual Congress.
Researchers answered our questions about their recent study, which suggested that noninvasive retinal imaging parameters should be investigated further as potential biomarkers of Parkinson disease.
Neurology Learning Network spoke with Rachel Saunders-Pullman, MD, MPH; Tanya Simuni, MD; and Tara Hastings, MA, who recently discussed clinical genetic testing for Parkinson disease at the American Neurological Association’s 145th Annual Meeting.
Alastair Noyce, MD, discusses his recent study, which found that patients with Parkinson disease have likely had less access to medication during the COVID-19 pandemic, which in turn may impact patients' symptomatic control.
Early findings presented at the International Parkinson and Movement Disorders 2020 Virtual Congress indicate that an α-synuclein active immunotherapeutic drug appears to be safe and well-tolerated, and generated a substantial humoral immune response with target engagement, among patients with Parkinson disease. Neurology Learning Network discussed these findings further with Joohi Jimenez-Shahed, MD.
In this podcast, Dr Shah discusses the imaging and treatment modalities he and his colleagues reviewed in their recent article, "Advanced MRI techniques for transcranial high intensity focused ultrasound targeting," which was published in the journal Brain.
New findings suggest that α-synuclein reactive T cells may be present years before the diagnosis of motor Parkinson disease. Neurology Consultant discussed these findings further with study author David Sulzer, PhD, from Columbia University Medical Center.
A new review indicates that newer, advanced MRI technology can serve as a “promising alternative” to subjective landmark-based methods for transcranial high intensity focused ultrasound targeting. Neurology Consultant discussed the implications of the review further with lead author Bhavya R. Shah, MD.
Allison Willis, MD, discusses efforts to address the "female paradox of Parkinson disease."
Gal Bitan, PhD, from UCLA, answers our questions about his research on a potential blood test for diagnosing PD, which can also distinguish between PD and multiple system atrophy.
Michael Banks, MD, discusses recent research on the association of anxiety and depression with freezing of gait in patients with Parkinson disease.